Remove Bioinformatics Remove RNA Remove Science
article thumbnail

Therapeutic Oligos 2025 Keynote Speakers Announced

Elrig

This second ELRIG meeting on Therapeutic Oligonucleotides brings together esteemed scientists from academia, industry, and other members of the drug discovery community to explore the discovery, validation, and targeting of oligonucleotide-based drug candidates, including antisense oligonucleotides (ASOs) and small interfering RNA (siRNA).

RNA 59
article thumbnail

MIA: Noor Pratap Singh, RNA-Seq data using a tree-based framework; Primer: Rob Patro

Broad Institute

To address these challenges, we introduce a data-driven tree-based framework that incorporates uncertainty into RNA-seq data analysis. In the first part of the talk, I will discuss existing approaches for handling uncertainty and their limitations in RNA-seq data analysis before introducing TreeTerminus.

RNA 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Scientific workflow for hypothesis testing in drug discovery: Part 1

Drug Target Review

This includes verifying the experimental design and understanding how the data was generated whether it was from RNA sequencing, mass spectrometry, or other biological assays. About the authors Dr Raminderpal Singh Dr Raminderpal Singh is a recognised visionary in the implementation of AI across technology and science-focused industries.

RNA 52
article thumbnail

Reaching cruising altitude: New discovery tools to target RNA

Dark Matter Blog

Our overall mission at Arrakis is to expand the set of “druggable” targets for small-molecule medicines to include RNA. Today, we are pleased to announce that our article describing one such platform: “ PEARL-seq, A Photoaffinity Platform for the Analysis of Small Molecule-RNA Interactions ” was published in ACS Chemical Biology.

RNA 52
article thumbnail

AI At The Frontier: Empowering Early Career Professionals In Drug Discovery

Elrig

With a background in Bioinformatics and Computational Biology, she has a keen interest in using technology to solve problems in healthcare and medicine. She has played a key role inbuilding the target identification platform and a proprietary database of transcriptome-wide, functional RNA structures.

article thumbnail

Kickstarting the use of AI for biotechs: part two

Drug Target Review

2 AlphaFold 3 has been built to model DNA, RNA and smaller molecules (ligands). 5 Several major technology areas are not included above, such as cheminformatics and bioinformatics. Google DeepMind’s new AI can model DNA, RNA, and ‘all life’s molecules’. The latest exciting advancement is AlphaFold 3, which was just released.

RNA 59
article thumbnail

Leveraging ADCs in precision oncology strategy

Drug Target Review

Caris Life Sciences® (Caris) has been at the forefront of precision medicine. Caris Discovery, the therapeutic research arm of Caris Life Sciences, was launched to address the paucity of novel oncology drug targets and is uniquely poised to discover first-in-class ADC targets.